Free Trial

Janney Montgomery Scott LLC Makes New Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Collegium Pharmaceutical logo with Medical background

Janney Montgomery Scott LLC bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,696 shares of the specialty pharmaceutical company's stock, valued at approximately $439,000.

Several other institutional investors and hedge funds have also made changes to their positions in COLL. Invesco Ltd. boosted its stake in Collegium Pharmaceutical by 19.5% during the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after acquiring an additional 289,335 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Collegium Pharmaceutical by 319.4% in the 4th quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock worth $8,341,000 after buying an additional 221,903 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Collegium Pharmaceutical in the 4th quarter worth about $3,489,000. Raymond James Financial Inc. bought a new position in shares of Collegium Pharmaceutical in the 4th quarter worth about $2,432,000. Finally, F M Investments LLC bought a new position in shares of Collegium Pharmaceutical in the 4th quarter worth about $2,096,000.

Insider Buying and Selling

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $30.62, for a total transaction of $202,122.62. Following the transaction, the director owned 70,658 shares of the company's stock, valued at approximately $2,163,547.96. This trade represents a 8.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock traded up $0.55 during trading hours on Monday, reaching $30.90. The stock had a trading volume of 431,680 shares, compared to its average volume of 399,434. The company has a debt-to-equity ratio of 3.30, a current ratio of 1.08 and a quick ratio of 1.01. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The firm has a 50-day simple moving average of $29.30 and a 200-day simple moving average of $29.51. The firm has a market capitalization of $992.82 million, a PE ratio of 25.33 and a beta of 0.64.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The firm's revenue was up 22.7% on a year-over-year basis. During the same period last year, the business earned $1.45 EPS. As a group, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical declared that its board has approved a stock buyback plan on Monday, July 7th that authorizes the company to buyback $150.00 million in outstanding shares. This buyback authorization authorizes the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler restated a "neutral" rating and issued a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Finally, Needham & Company LLC restated a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.75.

Read Our Latest Analysis on COLL

Collegium Pharmaceutical Profile

(Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Featured Articles

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Should You Invest $1,000 in Collegium Pharmaceutical Right Now?

Before you consider Collegium Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.

While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines